Literature DB >> 24014478

Improved synthesis of capuramycin and its analogues.

Yong Wang1, Shajila Siricilla, Bilal A Aleiwi, Michio Kurosu.   

Abstract

Capuramycin and its congeners are considered to be important lead molecules for the development of a new drug for multidrug-resistant (MDR) Mycobacterium tuberculosis infections. Extensive structure-activity relationship studies of capuramycin to improve the efficacy have been limited because of difficulties in selectively chemically modifying the desired position(s) of the natural product with biologically interesting functional groups. We have developed efficient syntheses of capuramycin and its analogues by using new protecting groups, derived from the chiral (chloro-4-methoxyphenyl)(chlorophenyl)methanols, for the uridine ureido nitrogen and primary alcohol. The chiral nonracemic (2,6-dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methanol derivative is a useful reagent to resolve rac-3-amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one, the (S)-configuration isomer of which plays a significant role in improving the mycobactericidal activity of capuramycin.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  capuramycin; drug design; mycobacterium tuberculosis; peptidoglycan biosynthesis; protecting groups; total synthesis

Mesh:

Substances:

Year:  2013        PMID: 24014478      PMCID: PMC3929971          DOI: 10.1002/chem.201302389

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  44 in total

1.  District-randomized phased implementation: strengthening the evidence base for cotrimoxazole for HIV-positive tuberculosis patients.

Authors:  Peter Godfrey-Faussett
Journal:  AIDS       Date:  2003-05-02       Impact factor: 4.177

2.  Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp.

Authors:  Masayuki Igarashi; Naoko Nakagawa; Norio Doi; Seiko Hattori; Hiroshi Naganawa; Masa Hamada
Journal:  J Antibiot (Tokyo)       Date:  2003-06       Impact factor: 2.649

3.  Chemical modification of capuramycins to enhance antibacterial activity.

Authors:  Elena Bogatcheva; Tia Dubuisson; Marina Protopopova; Leo Einck; Carol A Nacy; Venkata M Reddy
Journal:  J Antimicrob Chemother       Date:  2010-12-23       Impact factor: 5.790

4.  Polymer-supported (2,6-dichloro- 4-alkoxyphenyl)(2,4-dichlorophenyl)methanol: a new linker for solid-phase organic synthesis.

Authors:  Michio Kurosu; Kallolmay Biswas; Dean C Crick
Journal:  Org Lett       Date:  2007-02-21       Impact factor: 6.005

5.  Physics. Watching rush hour in the world of electrons.

Authors:  Jan Zaanen
Journal:  Science       Date:  2007-03-09       Impact factor: 47.728

6.  In vitro antimycobacterial activities of capuramycin analogues.

Authors:  Venkata M Reddy; Leo Einck; Carol A Nacy
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

7.  Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Authors:  A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

8.  Selective esterifications of primary alcohols in a water-containing solvent.

Authors:  Yong Wang; Bilal A Aleiwi; Qinghui Wang; Michio Kurosu
Journal:  Org Lett       Date:  2012-08-31       Impact factor: 6.005

9.  A reliable Pd-mediated hydrogenolytic deprotection of BOM group of uridine ureido nitrogen.

Authors:  Bilal A Aleiwi; Michio Kurosu
Journal:  Tetrahedron Lett       Date:  2012-05-12       Impact factor: 2.415

10.  A new protecting group and linker for uridine ureido nitrogen.

Authors:  Yong Wang; Michio Kurosu
Journal:  Tetrahedron       Date:  2012-04-09       Impact factor: 2.457

View more
  10 in total

1.  Substrate Tolerance of Bacterial Glycosyltransferase MurG: Novel Fluorescence-Based Assays.

Authors:  Katsuhiko Mitachi; Hyun Gi Yun; Cody D Gillman; Karolina Skorupinska-Tudek; Ewa Swiezewska; William M Clemons; Michio Kurosu
Journal:  ACS Infect Dis       Date:  2019-12-11       Impact factor: 5.084

2.  DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.

Authors:  Katsuhiko Mitachi; Rita G Kansal; Kirk E Hevener; Cody D Gillman; Syed M Hussain; Hyun Gi Yun; Gustavo A Miranda-Carboni; Evan S Glazer; William M Clemons; Michio Kurosu
Journal:  J Med Chem       Date:  2020-09-18       Impact factor: 7.446

3.  Fluorescence-based assay for polyprenyl phosphate-GlcNAc-1-phosphate transferase (WecA) and identification of novel antimycobacterial WecA inhibitors.

Authors:  Katsuhiko Mitachi; Shajila Siricilla; Dong Yang; Ying Kong; Karolina Skorupinska-Tudek; Ewa Swiezewska; Scott G Franzblau; Michio Kurosu
Journal:  Anal Biochem       Date:  2016-08-13       Impact factor: 3.365

4.  Chemoenzymatic syntheses of water-soluble lipid I fluorescent probes.

Authors:  Katsuhiko Mitachi; Shajila Siricilla; Lada Klaic; William M Clemons; Michio Kurosu
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

5.  A Convenient Protecting Group for Uridine Ureido Nitrogen: (4,4'-Bisfluorophenyl)methoxymethyl group.

Authors:  Katsuhiko Mitachi; David Mingle; Michio Kurosu
Journal:  Synthesis (Stuttg)       Date:  2021-03-25       Impact factor: 2.969

6.  Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.

Authors:  Shajila Siricilla; Katsuhiko Mitachi; Karolina Skorupinska-Tudek; Ewa Swiezewska; Michio Kurosu
Journal:  Anal Biochem       Date:  2014-06-02       Impact factor: 3.365

7.  Stereocontrolled Total Synthesis of Muraymycin D1 Having a Dual Mode of Action against Mycobacterium tuberculosis.

Authors:  Katsuhiko Mitachi; Bilal A Aleiwi; Christopher M Schneider; Shajila Siricilla; Michio Kurosu
Journal:  J Am Chem Soc       Date:  2016-09-26       Impact factor: 15.419

8.  Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.

Authors:  Shajila Siricilla; Katsuhiko Mitachi; Bajoie Wan; Scott G Franzblau; Michio Kurosu
Journal:  J Antibiot (Tokyo)       Date:  2014-10-01       Impact factor: 2.649

9.  Novel FR-900493 Analogues That Inhibit the Outgrowth of Clostridium difficile Spores.

Authors:  Katsuhiko Mitachi; Hyun Gi Yun; Sara M Kurosu; Shakiba Eslamimehr; Maddie R Lemieux; Lada Klaić; William M Clemons; Michio Kurosu
Journal:  ACS Omega       Date:  2018-02-09

Review 10.  Biosynthetic and Synthetic Strategies for Assembling Capuramycin-Type Antituberculosis Antibiotics.

Authors:  Ashley L Biecker; Xiaodong Liu; Jon S Thorson; Zhaoyong Yang; Steven G Van Lanen
Journal:  Molecules       Date:  2019-01-25       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.